Company intelligence

BCYC

Bicycle Therapeutics plc · NASDAQ · Healthcare

Price$4.39+1.39% · +$0.06

Market cap304.64MEquity value

P / E-1.6Trailing ratio

Volume209.9KLatest session

Market data

BCYC price chart

TradingView

Related signals

1 min delayed

Browse public BCYC signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BCYCAug 3, 2026+1.88% since signal

Visa to Acquire BioCatch for $2.4B in Cash, Expands Fraud Prevention

Visa announced plans to acquire BioCatch for $2.4 billion in cash, expanding its cybersecurity and fraud-prevention offerings. The deal highlights Visa's push to deepen risk analytics and device- and behavior-based detection across its payments network, potentially accelerating BioCatch's value realization for BCYC investors while regulatory approvals and closing timing pose risk.

View signal analysis

BCYCSep 6, 2024+25.65% since signal

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

RBC Capital initiated coverage on BCYC, highlighting oncology benefits. Zelenectide shows potential against metastatic urothelial cancer, rivaling Padcev. Improved safety of Zelenectide could enhance antitumor durability significantly. Analyst projects Zelenectide may reach ~$2 billion in peak sales by 2033. RBC rates BCYC as Outperform with a price target of $35.

View signal analysis

Research